Use of Immunotherapy With Programmed Cell Death 1 vs Programmed Cell Death Ligand 1 Inhibitors in Patients With Cancer: A Systematic Review and Meta-analysis.
Duan, Jianchun
Use of Immunotherapy With Programmed Cell Death 1 vs Programmed Cell Death Ligand 1 Inhibitors in Patients With Cancer: A Systematic Review and Meta-analysis. [electronic resource] - JAMA oncology 03 2020 - 375-384 p. digital
Publication Type: Journal Article; Meta-Analysis; Systematic Review
2374-2445
10.1001/jamaoncol.2019.5367 doi
Antineoplastic Agents, Immunological--therapeutic use
B7-H1 Antigen--antagonists & inhibitors
Humans
Immune Checkpoint Inhibitors--therapeutic use
Immunotherapy
Neoplasms--drug therapy
Programmed Cell Death 1 Receptor--antagonists & inhibitors
Randomized Controlled Trials as Topic
Use of Immunotherapy With Programmed Cell Death 1 vs Programmed Cell Death Ligand 1 Inhibitors in Patients With Cancer: A Systematic Review and Meta-analysis. [electronic resource] - JAMA oncology 03 2020 - 375-384 p. digital
Publication Type: Journal Article; Meta-Analysis; Systematic Review
2374-2445
10.1001/jamaoncol.2019.5367 doi
Antineoplastic Agents, Immunological--therapeutic use
B7-H1 Antigen--antagonists & inhibitors
Humans
Immune Checkpoint Inhibitors--therapeutic use
Immunotherapy
Neoplasms--drug therapy
Programmed Cell Death 1 Receptor--antagonists & inhibitors
Randomized Controlled Trials as Topic